US Vaccine Market Growth, Size, Trends, Demand, Revenue, Share, Competition and Future Outlook
United States Vaccine Market Size- By Product, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
| Published: Jan-2024 | Report ID: HLCA2401 | Pages: 1 - 108 | Formats*: |
| Category : Healthcare | |||
United States Vaccine Market Introduction and Overview
According to SPER Market Research, the United States Vaccine Market is estimated to reach USD 30.54 billion by 2033 with a CAGR of 7.5%.
The report includes an in-depth analysis of the United States Vaccine Market, including market size and trends, product mix, distribution channels, and supplier analysis. A vaccine is a biological preparation intended to offer protection against a particular infectious disease at the active stage. It usually consists of fractions of these microorganisms, like proteins or sugars, or weakened or inactivated forms of the pathogens, like bacteria or viruses. Getting the immune system to identify and remember these substances as foreign invaders is the main goal of a vaccination. A person's immune system reacts to vaccination by mounting an immunological response that includes the creation of immune cells and antibodies that are specifically directed against the vaccine's antigens.
-00707182012024.jpg)
Market Opportunities and Challenges
Opportunities: The vaccine market in the United States offers a wide range of opportunities due to a number of factors. First, a consistent demand for vaccines is fueled by rising awareness of preventive healthcare and a growing emphasis on immunization to fight infectious diseases. Innovation and the creation of new vaccines are encouraged by developments in biotechnology and vaccine research as well as significant investments in the healthcare industry. Furthermore, continuing efforts to address global health issues like the COVID-19 pandemic present chances for pharmaceutical companies and research institutions to work together on ground-breaking vaccine solutions.
Challenges: A number of factors affect the effectiveness and dynamics of the US vaccine market. A noteworthy obstacle is vaccine hesitancy, which refers to the reluctance or resistance of a segment of the population to receive vaccinations because of misgivings, misinformation, or safety concerns. This may hinder attempts to stop the spread of infectious diseases and develop broad immunity. Pharmaceutical companies face financial challenges due to the lengthy and resource-intensive regulatory approval process and the high cost of vaccine development. The number of businesses ready to contribute to the development of vaccines may be impacted by this.
-00707222012024.jpg)
Market Competitive Landscape
The United States Vaccine Market is slightly fragmented. Some of the market key players are AstraZeneca plc, Bharat Biotech, Berna Biotech Ltd., BIO-MED, Bilthoven Biologicals, Boehringer Ingelheim, Boehringer Ingelheim International GmbH, Cadila Healthcare Limited, Chiron Behring Vaccines Private Ltd, Elanco, GlaxoSmithKline plc, Sanofi Pasteur, Others.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2033 |
| Base year considered | 2022 |
| Forecast period | 2023-2033 |
| Segments covered | By Product, By End User |
| Regions covered | Eastern Region, Western Region, Southern Region, Northern Region |
| Companies Covered | AstraZeneca plc, Bharat Biotech, Berna Biotech Ltd., BIO-MED, Bilthoven Biologicals, Boehringer Ingelheim, Boehringer Ingelheim International GmbH, Cadila Healthcare Limited, Chiron Behring Vaccines Private Ltd, Elanco, GlaxoSmithKline plc, Sanofi Pasteur, Others. |
COVID-19 Impact on United States Vaccine Market
The COVID-19 pandemic has had a profound effect on the US vaccine market in a number of ways. An unprecedented worldwide race to develop and disseminate effective solutions was sparked by the urgent need for a vaccine to combat the novel coronavirus. The U.S. government's Operation Warp Speed, a public-private partnership, was instrumental in accelerating the development and distribution of vaccines. The pandemic highlighted the need for a strong vaccine infrastructure, which prompted higher spending on R&D, production, and distribution. Nonetheless, difficulties including managing vaccine hesitancy, providing fair access, and organizing vaccine distribution logistics surfaced.
Key Target Audience
- Healthcare Professionals
- Pharmaceutical Companies
- Government Health Agencies
- Research Institutions
- Public Health Organizations
Our in-depth analysis of the United States Vaccine Market includes the following segments:
| By Product: |
|
| By End User: |
|
| By Region: |
|
Key Topics Covered in the Report
- United States Vaccine Market Size (FY’2023-FY’2033)
- Overview of United States Vaccine Market
- Segmentation of United States Vaccine Market By Product (Human Vaccine, Animal Vaccine)
- Segmentation of United States Vaccine Market By End User (Hospitals, Clinics, Vaccination Centers)
- Expansion Analysis of United States Vaccine Market
- Problems and Obstacles in United States Vaccine Market
- Competitive Landscape in the United States Vaccine Market
- Impact of COVID-19 and Demonetization on United States Vaccine Market
- Details on Current Investment in United States Vaccine Market
- Competitive Analysis of United States Vaccine Market
- Prominent Players in the United States Vaccine Market
- SWOT Analysis of United States Vaccine Market
- United States Vaccine Market Future Outlook and Projections (FY’2023-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges
4.2. COVID-19 Impacts of the United States Vaccine Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. United States Vaccine Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in United States Vaccine Market
7. United States Vaccine Market, By Product (USD Million)
7.1. United States Vaccine Market Value Share and Forecast, By Product, 2023-20337.2. Human Vaccine
7.2.1. Pediatric Vaccines7.2.2. Adult & Adolescent Vaccines7.2.3. Others
7.3. Animal Vaccine
7.3.1. Livestock Vaccines7.3.2. Companion Animal Vaccines7.3.3. Others
8. United States Vaccine Market, By End User (USD Million)
8.1. United States Vaccine Market Value Share and Forecast, By End User, 2023-20338.2. Hospitals8.3. Clinics8.4. Vaccination Centers
9. United States Vaccine Market Forecast, 2019-2033 (USD Million)
9.1. United States Vaccine Market Size and Market Share
10. United States Vaccine Market, By Product, 2019-2033 (USD Million)
10.1. United States Vaccine Market Size and Market Share By Product (2019-2026)10.2. United States Vaccine Market Size and Market Share By Product (2027-2033)
11. United States Vaccine Market, By End User, 2019-2033 (USD Million)
11.1. United States Vaccine Market Size and Market Share By End User (2019-2026)11.2. United States Vaccine Market Size and Market Share By End User (2027-2033)
12. United States Vaccine Market, By Region, 2019-2033 (USD Million)
12.1. United States Vaccine Market Size and Market Share By Region (2019-2026)12.2. United States Vaccine Market Size and Market Share By Region (2027-2033)12.3. Eastern Region12.4. Western Region12.5. Southern Region12.6. Northern Region
13. Company Profile
13.1. AstraZeneca plc
13.1.1. Company details13.1.2. Financial outlook13.1.3. Product summary13.1.4. Recent developments
13.2. Bharat Biotech
13.2.1. Company details13.2.2. Financial outlook13.2.3. Product summary13.2.4. Recent developments
13.3. Berna Biotech Ltd.
13.3.1. Company details13.3.2. Financial outlook13.3.3. Product summary13.3.4. Recent developments
13.4. BIO-MED
13.4.1. Company details13.4.2. Financial outlook13.4.3. Product summary13.4.4. Recent developments
13.5. Bilthoven Biologicals
13.5.1. Company details13.5.2. Financial outlook13.5.3. Product summary13.5.4. Recent developments
13.6. Boehringer Ingelheim
13.6.1. Company details13.6.2. Financial outlook13.6.3. Product summary13.6.4. Recent developments
13.7. Boehringer Ingelheim International GmbH
13.7.1. Company details13.7.2. Financial outlook13.7.3. Product summary13.7.4. Recent developments
13.8. Cadila Healthcare Limited
13.8.1. Company details13.8.2. Financial outlook13.8.3. Product summary13.8.4. Recent developments
13.9. Chiron Behring Vaccines Private Ltd
13.9.1. Company details13.9.2. Financial outlook13.9.3. Product summary13.9.4. Recent developments
13.10. Elanco
13.10.1. Company details13.10.2. Financial outlook13.10.3. Product summary13.10.4. Recent developments
13.11. GlaxoSmithKline plc
13.11.1. Company details13.11.2. Financial outlook13.11.3. Product summary13.11.4. Recent developments
13.12. Sanofi Pasteur
13.12.1. Company details13.12.2. Financial outlook13.12.3. Product summary13.12.4. Recent developments
13.13. Others
14. List of Abbreviations
15. Reference Links
16. Conclusion
17. Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
You can get the sample pages by clicking the link - Click Here
United States Vaccine Market size is USD 30.54 billion from 2023 to 2033.
United States Vaccine Market Segment is covered By Product, By End User.
The North America is anticipated to have the highest market share in the United States Vaccine Market.
The key players in the market include Companies Covered AstraZeneca plc, Bharat Biotech, Berna Biotech Ltd., BIO-MED, Bilthoven Biologicals, Boehringer Ingelheim, Boehringer Ingelheim International GmbH, Cadila Healthcare Limited, Chiron Behring Vaccines Private Ltd, Elanco, GlaxoSmithKline plc, Sanofi Pasteur, Others.
A vaccine is a biological preparation intended to offer protection against a particular infectious disease at the active stage.
United States Vaccine Market is projected to reach USD 30.54 billion by 2033, growing at a CAGR of 7.5% during the forecast period.
United States Vaccine Market grew in market size from 2022. The Market is expected to reach USD 30.54 billion by 2033, at a CAGR of 7.5% during the forecast period.
United States Vaccine Market CAGR of 7.5% during the forecast period.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
